SLC5A2 and type 1 diabetes mellitus: Although the adjunctive use of SGLT2 inhibitors has shown these benefits in T1D, the above-cited RCTs and meta-analyses have revealed a significantly increased risk of diabetic ketoacidosis (DKA) as a serious adverse event of these drugs [6,7,8,9,10,11,12,18,19,20].